

NHS England ColoSTAT® Evaluation Commences

Highlights

- ✓ ColoSTAT® has entered independent evaluation within the NHS England bowel cancer screening system — one of the world's largest organised cancer screening programs — marking the first time ColoSTAT® has been assessed inside the NHS and a key step in the Company's international commercialisation strategy.
- ✓ Custom ColoSTAT® reagents and system components have been transferred to the Hub laboratory in Guildford, England, enabling the independent evaluation to commence.
- ✓ The NHS Southern Hub laboratory has confirmed the required laboratory commitment and resources to support the independent analytical and clinical evaluation of ColoSTAT® within the NHSE (National Health Service in England) environment.

Melbourne, Australia, 26th February 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to provide an update on the commencement of its collaboration with the Southern Hub Research Team based at the Royal Surrey NHS Foundation Trust and part of the Berkshire and Surrey NHS Pathology network ('the Hub') to evaluate ColoSTAT®.

As previously announced on 10th December 2025, Rhythm entered into a collaboration with the Hub to evaluate the suitability of ColoSTAT® for potential use within the bowel cancer screening pathway in England. The Company confirms that this evaluation has now formally commenced, following the successful transfer of custom ColoSTAT® reagents and system components to the Hub laboratory in Guildford, England, and the confirmation of the required laboratory commitment from the Hub team. A project initiation meeting was held at the Hub on 24th February 2026.

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

The Hub laboratory, which has extensive experience in the assessment of bowel cancer screening clinical tests, will first conduct an initial independent analytical performance evaluation of ColoSTAT[®]. This will be followed by a clinical evaluation in patients specifically recruited for the purpose. The full ColoSTAT[®] system — comprising instruments, reagents and software — is now in place at the Hub laboratory to support this work.

The NHS Bowel Cancer Screening Programme invites approximately 2.5 million people in England for screening each year. The Southern Hub at Royal Surrey NHS Foundation Trust is one of a small number of specialist NHS laboratories designated to independently evaluate new screening technologies before they can enter the national pathway — making a positive outcome here a meaningful step to positioning ColoSTAT[®] for potential access to one of the world's largest organised screening populations.

The NHS evaluation is expected to inform potential adoption pathways for ColoSTAT[®] within the NHS England bowel cancer screening framework, one of the largest organised cancer screening programs globally. A successful outcome may support future commercial opportunities in the UK and broader international markets.

This milestone represents the first independent evaluation of ColoSTAT[®] within the NHS system and is a key step toward clinical and commercial adoption in the UK. Dr David Atkins, Rhythm CEO & Managing Director commented “We are delighted that we were able to get the Hub equipped quickly to allow us to have the initiation meeting with Dr Benton and her team in Guildford, so soon after completing the agreement. The NHS represents one of the most significant commercial opportunities available to us globally, and we are moving quickly to demonstrate ColoSTAT[®]'s suitability for its bowel cancer screening framework”.

The Company will provide further updates as the evaluation progresses.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.